<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052347</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0490</org_study_id>
    <nct_id>NCT04052347</nct_id>
  </id_info>
  <brief_title>Decision Aid to Assist Low-Risk Nulliparous Women Considering Induction of Labor At 39 Weeks</brief_title>
  <acronym>DAWN</acronym>
  <official_title>Decision Aid to Assist Low-Risk Nulliparous Women Considering Induction of Labor At 39 Weeks: A Randomized Trial (DAWN Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess if the utilization of a decision-aid increases the&#xD;
      likelihood of low-risk nulliparous women undergoing elective induction of labor at 39.0-39.6&#xD;
      weeks&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Covid related&#xD;
  </why_stopped>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects who decided to undergo elective induction of labor at 39.0-39.6 weeks after utilization of a decision-aid</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of subjects who decided to undergo elective induction of labor at 39.0-39.6 weeks after utilization of a decision-aid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity</measure>
    <time_frame>at delivery</time_frame>
    <description>Composite neonatal morbidity among (CNM) is any of the following: 1) Apgar score &lt; 7 at 5 min, 2) umbilical arterial pH &lt; 7.00, 3) intraventricular hemorrhage grade III or IV, 4) periventricular leukomalacia, 5) intubation for over 24 hrs, 6) necrotizing enterocolitis grade 2 or 3, 7) stillbirth or 8) death within 28 days of birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidities</measure>
    <time_frame>1 week</time_frame>
    <description>Number of subjects with morbidities as described by American College of Obstetrics and Gynecology (ACOG)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Elective Induction</condition>
  <arm_group>
    <arm_group_label>Shared decision-making with a patient decision-aid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>routine shared decision-making</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Shared decision-making with a Decision-aid</intervention_name>
    <description>A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9</description>
    <arm_group_label>Shared decision-making with a patient decision-aid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>routine shared decision-making</intervention_name>
    <description>control group</description>
    <arm_group_label>routine shared decision-making</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Low-risk nulliparous women- no previous pregnancy &gt; 23 weeks&#xD;
&#xD;
          -  18-50 years of age&#xD;
&#xD;
          -  Singleton gestation&#xD;
&#xD;
          -  Between 34.0 and 36.6 weeks at the time of screening. Randomization must occur between&#xD;
             37.0-37.6 weeks inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. First sonographic examination after 20 weeks 2. Women with any of the following&#xD;
             comorbidities (at the time of randomization):&#xD;
&#xD;
               1. Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis,&#xD;
                  scleroderma)&#xD;
&#xD;
               2. Cerclage in the index pregnancy&#xD;
&#xD;
               3. Diabetes mellitus-gestational or pre-gestational&#xD;
&#xD;
               4. Hematologic disorders (coagulation defects, sickle cell disease,&#xD;
                  thrombocytopenia, thrombophilia)&#xD;
&#xD;
               5. Hypertension (chronic or pregnancy induced) before enrollment&#xD;
&#xD;
               6. HIV (human immunodeficiency virus)&#xD;
&#xD;
               7. Institutionalized individuals (prisoners)&#xD;
&#xD;
               8. Prior obstetric history of: 1) intrauterine growth restriction, 2) preterm birth&#xD;
                  before 34 weeks, 3) severe preeclampsia, eclampsia, HELLP syndrome, and 4)&#xD;
                  stillbirth after 24 weeks or neonatal death&#xD;
&#xD;
               9. Preterm labor or ruptured membranes before enrollment&#xD;
&#xD;
              10. Psychiatric disorder (bipolar, depression) on medication&#xD;
&#xD;
              11. Placenta previa / 3rd trimester bleeding&#xD;
&#xD;
              12. Renal insufficiency (serum creatinine &gt; 1.5 mg/dL)&#xD;
&#xD;
              13. Restrictive lung disease&#xD;
&#xD;
              14. Fetal red blood cell isoimmunization&#xD;
&#xD;
              15. Seizure disorder on medication&#xD;
&#xD;
              16. Thyroid disease on medication&#xD;
&#xD;
              17. Body Mass Index (BMI) above 40 kg/m 3. Major fetal Anomaly including:&#xD;
                  anencephaly, spina bifida, bilateral renal agenesis, cystic hygroma with hydrops,&#xD;
                  diaphragmatic hernia, or congenital heart defects 4. Unable to understand consent&#xD;
                  in English or Spanish&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sunbola S Ashimi Ademola</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

